The Public Health Agency of Canada (PHAC) Webinar for Health Care Providers
COVID-19 Vaccines Webinar: Recommendations of the National Advisory Committee on Immunization (NACI) on the use of the AstraZeneca vaccine
This moderated and live webinar includes a presentation and discussion on the NACI Recommendations for the use of the AstraZeneca vaccine, with live Q&A to inform health care and vaccine providers. This webinar is hosted by the National Collaborating Centre for Infectious Diseases (NCCID), in collaboration with the Public Health Agency of Canada (PHAC).
Presentation highlights:
- To describe the characteristics of the AstraZeneca COVID-19 vaccine platform.
- To outline the clinical evidence for the AstraZeneca COVID-19 vaccine.
- To summarize NACI recommendations on the use of the AstraZeneca COVID-19 vaccine.
- To present key information on handling and administering the AstraZeneca COVID-19 vaccine.
English Session
Moderator: April Killikelly, PhD, PHAC
Participants:
- Dr. Robyn Harrison, NACI
- Dr. Jesse Papenburg, NACI
- Dr. Martin Lavoie, NACI liaison from the Council of Chief Medical Officers of Health (CCMOH)
- Dr. Bryna Warshawsky, PHAC
- Michael Rosu-Myles and Leo Bouthillier, Health Canada
Please note that these webinars have been postponed. Check back here for updates.
French Session
Moderator: Andrea Gartley, BScN, PHAC
Participants:
- Dr. Jesse Papenburg, NACI
- Dr. Martin Lavoie, NACI liaison from the Council of Chief Medical Officers of Health (CCMOH)
- Charlene Young and Leo Bouthillier, Health Canada
Please note that these webinars have been postponed. Check back here for updates.
Please note, due to time limitations, not all questions can be answered. The same presentation will be delivered in English and in French. The webinars will be recorded and available on the NCCID website immediately following each event.
For any registration difficulties, please contact NCCID: nccid@umanitoba.ca
Previous Public Health Agency of Canada COVID-19 vaccine webinars can be found at Canada.ca and NCCID.